Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis

Abstract

On the basis of the available evidence and expert consensus, recommendations have been made for the use of rituximab as a treatment of ANCA-associated vasculitis. Further questions, in particular regarding long-term outcomes, remain to be explored.